Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, through its wholly owned subsidiary Napo Pharmaceuticals, has entered into a new manufacturing and supply agreement with Alivus Life Sciences dated July 9, 2026. Under this 2026 Agreement, Alivus will continue to manufacture crofelemer for use in Mytesi and other crofelemer-based human and animal products for Napo, its affiliates, or third parties designated by Napo.
The 2026 Agreement includes Napo’s commitment to purchase minimum quantities of crofelemer, with potential shortfall payments, subject to quarterly caps unless capacity is expanded at Napo’s written request. It runs through March 31, 2029, with options for successive renewals of at least two years, and allows termination for convenience with 12 months’ notice or for specified events, including uncured material breach, insolvency scenarios, regulatory withdrawal of crofelemer products, or chronic failure to supply. If an Insolvency Event occurs under a related license agreement, Napo’s rights and obligations under the 2026 Agreement for crofelemer manufacturing would be assigned to Woodward Specialty LLC.
Jaguar Health completed the previously announced conversion of its Series O Convertible Preferred Stock into common stock. Effective June 25, 2026, each share of Series O Preferred Stock converted into 3.209 shares of common stock.
Immediately after the conversion, Jaguar Health had 4,857,211 shares of common stock issued and outstanding. Holders of Eligible Warrants can receive up to 839,000 shares of common stock upon exercise, consisting of 68,593 warrant shares and 770,407 conversion shares linked to the Series O Preferred Stock dividend structure.
Jaguar Health, Inc. filed an 8-K describing two corporate updates. First, its Napo subsidiary and Woodward Specialty signed a First Amendment to their Manufacturing and Supply Agreement, clarifying how product inventory title transfers, keeping Napo in charge of managing inventory through December 31, 2026, with Woodward covering related costs.
Second, Jaguar elected to convert all Series O Convertible Preferred Stock into common stock, with each preferred share automatically converting into 3.209 shares of common stock at 12:00 pm Eastern Time on June 25, 2026. Holders will receive cash for any fractional common shares based on a price of $2.68 per share, and no action is required from them. The company also highlighted ongoing development of crofelemer for intestinal failure conditions and a planned NDA filing for microvillus inclusion disease in the first half of 2027.
Jaguar Health, Inc. filed an amended current report to replace an earlier press release exhibit with the correct version. The updated release confirms that the board has begun exploring a range of strategic alternatives aimed at maximizing shareholder value, following a review of current market conditions.
The company states it expects this strategic review process to align with completion of clinical work supporting a planned New Drug Application for its crofelemer drug candidate for rare intestinal failure diseases. Jaguar emphasizes that these are forward-looking statements subject to significant risks and uncertainties.
Jaguar Health, Inc. has started a formal process to explore a range of strategic alternatives aimed at maximizing shareholder value. The Board’s decision follows an evaluation of current market conditions.
The company expects the timing of this review to align with completion of clinical work supporting a planned New Drug Application for its crofelemer prescription drug candidate targeting rare intestinal failure diseases. Jaguar emphasizes that these plans are forward-looking and subject to significant risks and uncertainties described in its prior SEC reports.
Jaguar Health, Inc. entered several financing-related agreements affecting its royalty obligations, debt maturity, and equity structure. The company amended two royalty interests with Uptown Capital and Streeterville Capital, each originally for $12 million, so that beginning on October 1, 2026 the monthly royalty payment will be the greater of $750,000 or the royalty amount otherwise due under Section 2.1 of each agreement. Streeterville’s royalty amendment also pushes the start of monthly payments from July 1, 2026 to October 1, 2026.
Jaguar and its subsidiary Napo Pharmaceuticals also amended a secured promissory note originally issued to Streeterville in the principal amount of $6,220,812.50, extending the note’s maturity date from July 1, 2026 to October 1, 2026. In separate, privately negotiated exchange agreements with Streeterville, Jaguar issued 34,798, 36,796 and 38,655 common shares in three tranches in exchange for an aggregate 3.8, 3.4 and 3.68 shares of Series Q Perpetual Preferred Stock, respectively. The preferred shares received in each exchange were cancelled and retired, and in the aggregate the related common stock issuance exceeded 5% of Jaguar’s common shares outstanding as last reported in its most recent Form 10-Q.
Jaguar Health arranged two linked financings to bolster access to capital and liquidity. The company entered a common stock equity line of credit with an institutional investor, who is committed to purchase up to $40 million of Jaguar’s common stock, subject to volume, dollar and 4.99% beneficial ownership limits.
Jaguar will issue $800,000 of commitment shares valued at the VWAP on the ELOC registration statement’s effective date, and will register both these and future ELOC shares on a Form S-1. Separately, the company completed a private placement of 240 shares of Series P preferred stock for $2 million, carrying an 8% annual dividend payable in cash or stock.
The preferred stock has no conversion rights but features complex mandatory, optional and forced redemption mechanics, often settled in common shares using price-based formulas, plus 4.99%–9.99% beneficial ownership caps and 19.99% issuance limits tied to stockholder approvals and Nasdaq rules.
Jaguar Health, Inc. reported the final voting results of its 2026 Annual Meeting of Stockholders, where all five proposals were approved. The meeting, originally held May 22 and adjourned twice, reconvened on June 8, 2026 with 7,169,152 shares represented out of 14,044,277 shares entitled to vote as of April 15, 2026.
Stockholders elected director nominee John Micek III and approved additional proposals, each receiving millions of votes in favor with broker non-votes reported where applicable. Jaguar also highlighted that founder, president and CEO Lisa Conte is scheduled to present virtually at the Emerging Growth Conference on June 10, 2026.
Jaguar Health, Inc. entered two privately negotiated exchange agreements with Streeterville Capital to swap Series Q Perpetual Preferred Stock for common shares and further adjourned its 2026 Annual Meeting of Stockholders.
On May 26, 2026 the company issued 31,958 common shares in exchange for 3.72 Series Q preferred shares, which were then cancelled. On June 1, 2026 it issued 32,710 common shares in exchange for 4.2 additional Series Q preferred shares, which were also cancelled. These exchanges were completed under Section 3(a)(9) of the Securities Act.
The 2026 Annual Meeting, previously adjourned, was further adjourned to June 8, 2026 at 8:30 a.m. Pacific Time at Jaguar Health’s San Francisco offices, with the record date remaining April 15, 2026. Stockholders who have already voted and do not wish to change their vote do not need to take any action.
Jaguar Health, Inc. has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company on May 26, 2026, and its shares continue to trade on Nasdaq, although a Nasdaq Hearings Panel will retain jurisdiction over the listing until September 1, 2026.
The company is now subject to a one-year Mandatory Panel Monitor period through May 26, 2027. If during this time the closing bid falls below $1.00 per share for 30 consecutive business days, Nasdaq would issue a delist determination without granting the usual 180‑day grace period, though Jaguar could request a new hearing.
In the accompanying press release, Jaguar highlighted that net revenue in Q1 2026 increased 816% versus Q1 2025 and 527% versus Q4 2025, driven by a U.S. out‑license agreement for Mytesi and Canalevia‑CA1 with Future Pak. The company also reiterated its focus on a pivotal‑stage development program for crofelemer in rare intestinal failure indications, targeting a new drug application around mid‑2027 and seeking a development and commercialization partner.